Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 27Lymphoma, Mantle-Cell 14Lymphoma, Non-Hodgkin 13Lymphoma, B-Cell 11Lymphoma, B-Cell, Marginal Zone 7Hematologic Diseases 7Waldenstrom Macroglobulinemia 6Lymphoma 4Leukemia, B-Cell 4Lymphoma, Follicular 3Leukemia 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Lymphoid 2Dendritic Cell Sarcoma, Interdigitating 2Syndrome 1Multiple Myeloma 1Hematologic Neoplasms 1Chromosome 17 deletion 1Burkitt Lymphoma 1

Interventions

pirtobrutinib 1Surveys and Questionnaires 1Infliximab 1Educational Status 1Control Groups 1Acupressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Syndrome × pirtobrutinib × Clear all
NCT05172700 2024-12-18

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Eli Lilly and Company

Approved for marketing
LymphoidOther hematologic neoplasm

Hematologic Diseases, Waldenstrom Macroglobulinemia, Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡